Abstract
Castration-resistant prostate cancer (CRPC) poses a significant challenge in the medical field. The study developed a novel model, the branching bivariate Weibull distribution (BBWD), tailored to address CRPC and stems from the maximum likelihood estimation (MLE) function. It considers a medicinal biosystem aimed at transitioning androgen-dependent prostate cancer into an androgen-independent state. The BBWD model is designed to optimize the solution for bio variables pertinent to CRPC and evaluate various treatment techniques for androgen-dependent and androgen-independent behaviour. Through rigorous analysis, the kinetics of LINC01213 in androgen-deprived mediums are highlighted as promising, showing superior efficacy in castration compared to other techniques. The model utilizes the joint effect on the log-likelihood function (JELF) as a crucial analytical tool to assess the impact of LINC01213 in both normal and androgen-deprived medium. The results affirm the veracity of statements made within the medical field and support the notion that LINC01213 may serve as a novel therapeutic target for CRPC patients. The analysis underscores the pivotal role of exosomal LINC01213 in androgen-dependent prostate cancer, demonstrating its significance in treatment efficacy. The BBWD model highlighting the efficacy of LINC01213 in androgen-deprived mediums provides compelling evidence for its potential as a therapeutic target. This study corroborates existing medical hypotheses and offers detailed clarification and reports on treatment techniques for prostate cancer patients. Ultimately, it emphasizes the critical role of exosomal LINC01213 in addressing the challenges posed by androgen-dependent prostate cancer, offering a pathway toward more effective treatments.